Price Of Snakebite Drug Is Sky High, But New Competitor Unlikely To Lower Costs
The drug CroFab, which has been on the market since 2000, now faces competition from a drug called Anavip. But both are expensive.
Drugs
741 - 760 of 1,297 Results
-
-
Federal Expertsâ Advice On HPV Vaccine Could Leave Adults Confused
A federal advisory panel says people between ages 27 and 45 may benefit from the vaccine to fight the human papillomavirus. But some public health advocates worry that the advice doesnât provide doctors and patients clear guidance about who in this large age group are good candidates for the vaccine.
-
Drugmakers Master Rolling Out Their Own Generics To Stifle Competition
Known as âauthorized generics,â in-house spinoffs of brand-name drugs quietly undermine the competition.
By Jay Hancock and Sydney Lupkin -
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health care policy stories each week, so you donât have to.
-
Infusion Treatments â Needed or Not â Can Deplete Patientsâ Wallets
When it comes to physician-administered infusion drugs, doctors sometimes have a financial reason for their choice and patients often arenât aware of cheaper options.
-
Podcast
KHNâs âWhat The Health?â: Deciphering The Democratsâ Health Debate
Health care was a major topic at the Democratic presidential candidate debates in Detroit on Tuesday and Wednesday, but the focus on plan minutiae may have left viewers more confused than edified. Alice Ollstein of Politico, Kimberly Leonard of the Washington Examiner and Caitlin Owens of Axios join KHNâs Julie Rovner to discuss the points made by the candidates plus a series of Trump administration health initiatives on drug prices and hospital shopping.
-
California Bill Would Fight Deals That Delay Generic Drugs
As California Attorney General Xavier Becerra cracks down on pharmaceutical companies he said paid competitors to delay generic versions of their drugs, heâs also pushing for legislation that would give his department tools to catch more of them. Itâs the first of its kind in the nation.
-
Trump Administration âOpen For Businessâ On Drug Imports From Canada
HHS secretary announces a preliminary plan Wednesday to allow Americans to import certain lower-cost drugs from Canada. Manufacturers were quick to criticize the plan, saying it does not guarantee the safety of drugs coming into the country.
-
Trump Administration Moves To Make Health Care Costs More Transparent
The proposed rules would require hospitals to provide far more detail about the actual prices they charge insurers for patientsâ care.
-
New Protocol For HIV Prevention Drug Reduces The Number Of Pills Required
Health officials and AIDS advocates in San Francisco have endorsed a new regimen for PrEP medication: to be taken only immediately before and after sex, thus reducing cost and potential side effects. The standard regimen is one pill a day for an open-ended period.
By David Tuller -
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health care policy stories each week, so you don't have to.
-
Klobuchar Says D.C. Has Enough Drug Lobbyists To Double-Team Lawmakers
The drug industry has the biggest lobbying war chest.
-
GOP Senators Distance Themselves From Grassley And Trumpâs Efforts To Cut Drug Prices
Even some Republicans who supported a sweeping bipartisan bill to rein in drug costs may not back it in the Senate vote.
-
KHNâs âWhat The Health?â: Cue The Drug Price Debate
Democrats and Republicans on the Senate Finance Committee unveiled their long-awaited proposal to try to rein in prescription drug costs, even as bipartisan leaders of the other Senate committee that oversees health announced it would not bring its drug price bill to the Senate floor until fall. Paige Winfield Cunningham of The Washington Post, Rebecca Adams of CQ Roll Call and Alice Miranda Ollstein of Politico join KHNâs Julie Rovner to discuss this, plus court actions on health issues.
-
Summer Setbacks: The Long Road To Lower Drug Prices Hits Some Potholes
Efforts to control drug prices seemed on a glide path earlier this year after gaining traction at the White House and in Congress. But prospects today look less certain and highly controversial.
-
A Conservative Group Paints Trumpâs Drug-Pricing Experiment As âSocialist.â Is It?
The Americans for Tax Reform commercial takes too broad a brush against an initiative under consideration by the administration that would be part of the presidentâs promise to curb high drug prices.
-
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health care policy stories each week, so you don't have to.
-
KHNâs âWhat The Health?â: Biden Doubles Down On Obamacare
Presidential candidate Joe Biden unveiled a health plan intended to provide a more moderate alternative to his competitorsâ âMedicare for Allâ plans. It would build on the Affordable Care Act but would go much further. Margot Sanger-Katz of The New York Times, Joanne Kenen of Politico and Kimberly Leonard of the Washington Examiner join KHNâs Julie Rovner to discuss this, plus Planned Parenthoodâs very bad week, the U.S. House vote to repeal the health lawâs âCadillac taxâ on generous health plans, and the reduction in deaths from opioids.
-
KHN Investigation On Opioid Prescribers Pains Some Readers And Tweeters
Kaiser Health News gives readers a chance to comment on a recent batch of stories.
-
Common Medications Can Masquerade As Dementia In Seniors
A wide variety of medications used to treat allergies, insomnia, leaky bladders, diarrhea, dizziness, motion sickness, asthma, Parkinsonâs disease, chronic obstructive pulmonary disease and psychiatric disorders can interfere with cognition in older patients.